Journal article
Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression
YJC Song, GM Halliday, JL Holton, T Lashley, SS Osullivan, H McCann, AJ Lees, T Ozawa, DR Williams, PJ Lockhart, TR Revesz
Journal of Neuropathology and Experimental Neurology | Published : 2009
Abstract
The reactive changes in different types of astrocytes were analyzed in parkinsonian syndromes in order to identify common reactions and their relationship to disease severity. Immunohistochemistry was used on formalin-fixed, paraffin-embedded sections from the putamen, pons, and substantia nigra from 13 Parkinson disease (PD), 29 multiple-system atrophy (MSA), 34 progressive supranuclear palsy (PSP), 10 corticobasal degeneration(CBD), and 13 control cases. Classic reactive astrocytes were observed in MSA, PSP, and CBD, but not PD cases; the extent of reactivity correlated with indices of neurodegeneration and disease stage. Approximately 40% to 45% of subcortical astrocytes in PD and PSP acc..
View full abstractGrants
Awarded by BrainNet Europe II
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
Sources of support: Y.J.C.S. was an Australian Postgraduate and Parkinson's NSW Scholar and also funded by a GlaxoSmithKline Australia Postgraduate Support Grant. G.M.H. is a Principal Research Fellow of the National Health and Medical Research Council of Australia. T.R., J.L.I-I., and A.J.L. are supported by grants from Sara Matheson Trust for Multiple System Atrophy (Margaret Watson Memorial Grant), Alzheimer's Research Trust, and Grant No. LSHM-CT-2004-503039 from the BrainNet Europe II. Some of this work was undertaken at the University College London Hospitals and University College London, which received a proportion of funding from the Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme. Tissues were received from the Prince of Wales Medical Research Institute HumanTissue Resource Centre, which is supported by Enabling Grant No. 282933 from the National Health and Medical Research Council of Australia, and the Prince of Wales Medical Research Institute and from the Queen Square Brain Bank, which are supported by the Reta Lila Weston Institute for Neurological Studies and the Progressive Supranuclear Palsy (Europe) Association.